Clinical trials: Digestive System Cancer
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Fallopian Tube Cancer
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00318370
- Testing
- Farletuzumab, Chemo Plus Far
- Where
- 20 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Morphotek
Advanced or Metastatic Solid Tumor, Liver Failure
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
- Trial name
- NCT04617522
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Pancreas Cancer
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
- Trial name
- NCT04203641
- Testing
- L-DOS47, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Helix BioPharma Corporation
Hepatocellular Carcinoma
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard…
- Trial name
- NCT05072041
- Testing
- Nexsphere™
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Next Biomedical Co., Ltd.
Fatigue Related to Cancer Treatment, Colon Cancer
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.
- Trial name
- NuvastaticTM (NCT07669454)
- Testing
- Nuvastatic 300
- Where
- 6 sites in India
- Volunteers
- 250 people
- Sponsor
- Natureceuticals Sdn Bhd
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill more tumor cells.
- Trial name
- NCT00026273
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 15 sites in Austria, Belgium and 8 more
- Sponsor
- Pfizer
Hepatocellular Carcinoma, Hepatocellular Cancer
Characterization of Methylation Patterns in Hepatocellular Carcinoma
This study is being performed as part of the development process of the Liver EpiCheck test which includes the identification of different methylation profiles in HCC (hepatocellular carcinoma) patients compare to cancer free…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Cirrhosis
- Trial name
- NCT04264754
- Testing
- Blood collection
- Where
- 5 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Nucleix Ltd.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
Hepatocellular Carcinoma, Metastatic Cancer
Holmium-166 Retrospective Collection of Real-World Data
The primary objective of the study is to further describe the general safety and clinical performance of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres in a real-world post-market setting…
- Trial name
- RECORD (NCT05111795)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres
- Where
- 12 sites in Belgium, Germany and 5 more
- Volunteers
- 146 people
- Sponsor
- Terumo Europe N.V.
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Cancer, Pain
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone alone in patient's specific type of "chronic cancer pain".
- Conditions
- Cancer, Pain, Constipation
- Trial name
- NCT00513656
- Testing
- Oxycodone, Oxycodone/Naloxone
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Breast Cancer, Prostate Cancer
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01943500
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Viatar LLC
Gastric Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
The purpose of this study is to estimate objective response rates (ORRs) of pembrolizumab + oxaliplatin + TS-1 and pembrolizumab + cisplatin + TS-1, as first-line treatment for gastric cancer in programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03382600
- Testing
- Pembrolizumab, Oxaliplatin, TS-1
- Where
- 25 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
- Trial name
- NCT04468607
- Testing
- BLYG8824A
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Gastric Cancer
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.
This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for…
- Trial name
- NCT00436241
- Testing
- Oxaliplatin, capecitabine [Xeloda]
- Where
- 13 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Adenoid Cystic Carcinoma, Colorectal Cancer
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
- Trial name
- NCT06462183
- Testing
- RGT-61159, lenvatinib
- Where
- 9 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Rgenta Therapeutics Inc
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Advanced Hepatocellular Carcinoma
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced…
- Trial name
- NCT04000737
- Testing
- Sorafenib+YIV-906
- Where
- 24 sites in United States, China and 2 more
- Volunteers
- 62 people
- Sponsor
- Yiviva Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.